ALB and chronic kidney disease: Heerspink HJL et al. [19] studied, in a randomized clinical trial (RCT), the effect of dapagliflozin in 4304 patients with CKD with or without DM, with an eGFR of 25 to 75 mL/min/1.73 m2 and a urinary albumin-to-creatinine ratio (UACR) of 200 to 5000 mg/g.